RxDoctor Payments Data

Zael Vazquez, MD

Pulmonary Disease · Hollywood, FLNPI 1578723524

Payments from drug & device makers

$18,948in general payments, 2019–2025

Across 803 payments — averaging $23.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • GSK$2K
  • Actelion Pharmaceuticals US, Inc.$2K
  • Mallinckrodt Hospital Products Inc.$2K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Boehringer Ingelheim$1K
  • plus $8K from 37 others

What the payments were for

  • Food & beverage$18,74399%
  • Education$2051%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,948 in reported general payments places this provider in the 75th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$539,011
Medicare patients
587
Services billed
6,121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UptraviSelexipag30$509,395
AdempasRiociguat35$469,063
OfevNintedanib Esylate29$338,625
Trelegy ElliptaFluticasone/Umeclidin/Vilanter475$332,064
Breztri AerosphereBudesonide/Glycopyr/Formoterol160$108,243
Dupixent PenDupilumab24$89,724
NucalaMepolizumab11$39,287
EliquisApixaban31$20,467
Atrovent HfaIpratropium Bromide45$20,348
SymbicortBudesonide/Formoterol Fumarate43$13,173
Stiolto RespimatTiotropium Br/Olodaterol Hcl23$12,620
Combivent RespimatIpratropium/Albuterol Sulfate25$12,165
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate75$11,965
Albuterol Sulfate HfaAlbuterol Sulfate454$10,084
Breo ElliptaFluticasone/Vilanterol19$7,538

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi$1,729$509,39530 claims
BayerAdempas$543$469,06335 claims
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Incruse Ellipta$2,349$383,415518 claims
Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat, Spiriva Respimat$1,297$369,10088 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,541$121,416203 claims
PfizerEliquis$15$20,46731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Hollywood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →